公开(公告)号：US20190233522A1

公开(公告)日：2019-08-01

申请号：US16316000

申请日：2017-07-07

Applicant: GENMAB A/S

Inventor： Ulf FORSSMANN ,  Steen LISBY ,  Nedjad LOSIC

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.